Additional diagnostic evaluations included: the TDM of both TB drugs (such as rifampicin, levofloxacin, linezolid, etc.)and, in some cases, of co-medications (such as antipsychotics, antiepileptic drugs); frequent electrolyte monitoring (mainly for the risk associated with hypokalemia); and pharmacogenetic tests (N-acetyltransferase 2 (NAT2) for the geno-phenotyping of isoniazid and in two cases for the genotyping of cytochrome 2 C19 (CYP2C19) to facilitate encoding for the key metabolic enzyme involved in the activation of clopidogrel). Here, CYP2C19 is linked to tuberculosis.